CD40-CD40 Ligand Interactions Are Critical in T-B Cooperation but Not for Other Anti-viral CD4+ T Cell Functions

By A. Oxenius,* K.A. Campbell,‡ C.R. Maliszewski,‡ T. Kishimoto,§ H. Kikutani,‖ H. Hengartner,* R.M. Zinkernagel,* and M.E Bachmann*

From the *Institute for Experimental Immunology, Department of Pathology, University of Zürich, CH-8091 Zürich, Switzerland; ‡Departments of Cellular Immunology/Immunobiology, Immunex Corporation, Seattle, Washington 98101; §Department of Medicine III, Osaka University Medical School, Japan; and ‖Institute for Molecular and Cellular Biology, Osaka University, Division of Immunology, Osaka 565, Japan

Summary

CD40-CD40 ligand (CD40L) interaction is required for the generation of antibody responses to T-dependent antigens as well as for the development of germinal centers and memory B cells. The role of the CD40-CD40L interaction in the induction of antigen-specific Th cells and in mediating Th cell effector functions other than cognate help for B cells is less well understood. Using CD40- and CD40L-deficient mice together with lymphocytic choriomeningitis virus and vesicular stomatitis virus as viral model antigens, this study corroborates earlier findings that no Ig isotype switching of virus-specific antibodies was measurable upon infection of CD40- or CD40L-deficient mice. In contrast, in vivo induction of virus-specific CD4+ T cells measured by proliferation and cytokine secretion of primed virus-specific Th cells in vitro was not crucially dependent on the CD40-CD40L interaction. In addition, virus-specific Th cells primed in a CD40-deficient environment, adoptively transferred into CD40-competent recipients, were able to mediate Ig isotype switch. Th-mediated effector functions distinct from and in addition to T-B collaboration were analyzed in CD40- and CD40L-deficient and normal mice: (a) local inflammatory reactions upon LCMV infection mediated by LCMV-specific Th cells were not dependent on a functional CD40-CD40L interaction, (b) cytokine-mediated protection by CD4+ T cells primed by vesicular stomatitis virus against a challenge infection with recombinant vaccinia virus expressing the glycoprotein of vesicular stomatitis virus was found to be equivalent in CD40L-deficient and normal mice.

Thus, CD40-CD40L interaction plays a crucial role in T-B interactions for Th-dependent activation of B cells but not, or to a much lesser extent, in T cell activation, antigen-specific Th cell responses in vitro, and for interleukin-mediated Th cell effector functions in vivo.

It has been established both in vitro and in vivo that the interaction between CD40 on B cells and its ligand CD40L, which is expressed on activated Th cells, is required for Ig isotype switching, Ig-production and the formation of germinal centers (1–8). In vivo, administration of anti-CD40L antibody or soluble CD40L (9, 10) or CD40-Ig fusion protein (1) as well as studies in CD40- or CD40L-deficient mice (11–13) have shown that the generation of primary and secondary humoral immune responses and the formation of germinal centers to a variety of thymus-dependent antigens were abrogated. Furthermore, patients with hyper-IgM (HIGM) syndrome, a genetic disorder due to mutations in the CD40L gene, exhibit an inability to respond to thymus-dependent antigens and have secondary lymphoid organs which are devoid of germinal centers. Nevertheless, patients suffering from HIGM syndrome were able to mount a normal primary antibody response, indicating that CD40-CD40L interaction may be dispensable for primary immune responses.

Abbreviations used in this paper: DNP, dinitrophenol; HEL, hen egg lysozyme; HIGM, hyper-IgM syndrome; KLH, keyhole limpet hemocyanin; LCMV, lymphocytic choriomeningitis virus; LCMV-DNP, DNP covalently coupled to LCMV; OVA, ovalbumin; VacCGIND, recombinant vaccinia virus expressing VSV glycoprotein; VSV, vesicular stomatitis virus.

*Authors for correspondence.
baculovirus was derived from nuclear polyhedrosis virus and was grown on L929 cells (ATCC CR.L 1; American Type Culture Collection, Rockville, MD) (25). Recombinant viruses were propagated in spinner cultures in Spodoptera frugiperda cells in spinner cultures in TC-100 medium. Recombinant proteins were produced as previously described (27).

T Cell Proliferation. Mice were immunized intravenously with 200 PFU LCMV-WE. 14 d later, CD4+ T cells were purified from spleen cell suspensions by MACS-sorting according to the protocol of the supplier (Miltenyi Biotec, Bergisch Gladbach, Germany). 1 × 10^5 CD4+ T cells were incubated in 96-wells with threefold serial dilutions of either purified, UV-inactivated LCMV (concentrations shown for CD40L-/-, CD40-/-, IgM-/- and C57BL/6 ranged between 0.1 µg/ml and 1 µg/ml), P13 (concentrations shown for CD40L-/-, CD40-/-, IgM-/-, and C57BL/6 ranged between 0.1 µg/ml and 1 µg/ml) or medium only in the presence of 7 × 10^7 irradiated (2000Gy) C57BL/6 spleen cells for 3 d. Proliferation was assessed by incorporation of [3H]thymidine (25 µCi/well). P13 represents an I-Aα-restricted T cell epitope of the glycoprotein of LCMV which has been described elsewhere (28). We have previously shown that P13 is presented in vivo during a primary immune response against LCMV and that P13-specific CD4+ T cells are induced in vivo (28).

Cytokine Analysis. Supernatants of proliferation assays as described above were analyzed for IL-2 content (24 h after restimulation), IFNγ content (60 h after restimulation), and IL-4 content (60 h after restimulation). IL-2 was determined using the IL-2-directed cell line CTLL-2. Quantitation of viable cells was performed by AlamarBlue™ color reaction (Biosource, International, Camarillo, CA) and measured by fluorescence emission at 590 nm using the CytoFluor™ 2350 (Millipore Corp., Bedford, MA) fluorometer. IFNγ and IL-4 were assessed by ELISA as described (29, 30).

Adoptive Transfer of Primed Th Cells Followed by Challenge with DNP-modified LCMV. CD40-deficient and CD40-competent mice as well as IgM-deficient mice were immunized with 200 PFU of LCMV-WE into both hind foot pads. 18 d later, single cell suspensions were prepared from spleens. 6 × 10^7 primed spleen cells or an equivalent number of naive cells were transferred intravenously into naive, sex-matched C57BL/6 recipients. Donor cells were pooled from two to three individuals. A few hours later mice were challenged intravenously with 0.4 µg of purified LCMV to which DNP has been covalently coupled (LCMV-DNP) (31). Mice were bled 9 d later and DNP-specific IgG titers were determined by ELISA. The optimal dose for the challenge immunization with LCMV-DNP was determined by in vivo titration of the LCMV-DNP stock in naive versus LCMV-primed mice. The optimal dose was chosen such that only LCMV-primed mice but not naive mice gave rise to a DNP-specific IgG titer.

In addition, the same adoptive transfer experiment was performed using purified, LCMV-primed CD4+ T cells for transfer. CD40-deficient and heterozygous littermates were immunized with 200 PFU of LCMV-i.v. 14 d later, CD4+ T cells were purified from spleen cell suspensions by MACS-sorting according to the protocol of the supplier (Miltenyi Biotec). Mice were used at a purity of at least 95% as checked by FACS analysis. The optimal dose for the challenge immunization with LCMV-DNP was determined by in vivo titration of the LCMV-DNP stock in naive versus LCMV-primed mice. The optimal dose was chosen such that only LCMV-primed mice but not naive mice gave rise to a DNP-specific IgG titer. Mice were bled 10 d later and DNP-specific IgG titers were determined by ELISA.

ELISA. The LCMV nucleoprotein-specific ELISA has been described previously (26). 96-well plates (Petra Plastik, Chur, Switzerland) were incubated with LCMV nucleoprotein (0.01
μg/well) in 0.1 M NaH₂PO₄, pH 9.4, at 4°C. Plates were then preincubated with 2% bovine serum albumin in phosphate-buffered saline for 2 h and washed, and serial dilutions of serum samples (30-fold prediluted) were added to the wells and incubated for 90 min. Plates were washed and incubated with horseradish peroxidase-labeled goat anti-mouse IgG (Sigma Chem. Co., St. Louis, MO). After 90 min, plates were washed and developed with ABTS (5 mg of 2,2'-azino-di-3-ethyl-benzthiazolinsulfonate and 20 μl of H₂O₂ in 50 ml of NaHCO₃ [pH 4]). Optical densities were determined at 405 nm.

ELISA-measurement of DNP-specific IgG titers was performed similarly. ELISA plates were coated with 0.25 μg/well of Ovalbumin covalently coupled to DNP (31, 32).

VSV-specific Serum Neutralization Test. Neutralizing titers of sera were determined as described (33). Sera were prediluted 40-fold in supplemented MEM and heat-inactivated for 30 min at 56°C. Serial twofold dilutions were mixed with equal volumes of virus diluted to contain 500 PFU/ml. The mixture was incubated for 90 min at 37°C in an atmosphere containing 5% CO₂. 100 μl of the serum-virus mixture were transferred onto Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. The monolayers were then overlaid with 100 μl DMEM containing 1% methyl cellulose. After incubation for 24 h at 37°C the overlay was removed and the monolayer was fixed and stained with 0.5% crystal violet. The highest dilution of the serum that reduced the number of plaques by 50% was taken as the neutralizing titer. To determine IgG titers, undiluted serum was first pre-treated with an equal volume of 0.1 M 2-ME in saline (34).

Assessment of Foot Pad Swelling. Mice were inoculated with 30 PFU of LCMV-WE into both hind foot pads and foot pad swelling was assessed daily with a spring-loaded caliper (35). In vivo anti-CD4 treatment was performed at day 6 and 8 after infection.

Neutralizing titers of sera were determined as described (33). Sera were prediluted 40-fold in supplemented MEM and heat-inactivated for 30 min at 56°C. Serial twofold dilutions were mixed with equal volumes of virus diluted to contain 500 PFU/ml. The mixture was incubated for 90 min at 37°C in an atmosphere containing 5% CO₂. 100 μl of the serum-virus mixture were transferred onto Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. The monolayers were then overlaid with 100 μl DMEM containing 1% methyl cellulose. After incubation for 24 h at 37°C the overlay was removed and the monolayer was fixed and stained with 0.5% crystal violet. The highest dilution of the serum that reduced the number of plaques by 50% was taken as the neutralizing titer. To determine IgG titers, undiluted serum was first pre-treated with an equal volume of 0.1 M 2-ME in saline (34).

Protection of Mice from Replication of Recombinant Vaccinia Virus. Mice were immunized with 2 × 10⁶ PFU VSV and challenged i.p. 8 d later with 5 × 10⁶ PFU recombinant vaccinia virus expressing VSV-glycoprotein (VaccGpL). Vaccinia titers in ovaries were determined 5 d later as described previously (37). Titers are shown as log10 PFU per animal.

Results

Induction of Virus-specific Th Cells. In some experimental systems B cells have been shown to be crucial for efficient T helper cell induction (38-44). In addition, CD40 is not solely expressed on B cells but also on dendritic cells and follicular dendritic cells (6). We addressed therefore the question whether CD40-CD40L interaction or the presence of B cells serving as antigen presenting cells is required for the induction of virus-specific Th cells in vivo. We compared the induction of LCMV-specific Th cells in vivo in CD40-deficient, CD40L-deficient, normal C57BL/6, and IgM-deficient mice. Since it can be expected that B cells do not serve efficiently as APCs in the absence of proper activation and proliferation induced by the CD40-CD40L interaction, IgM-deficient mice that do not have peripheral B cells (24) were included in this comparison. This made possible the distinction between Th cell induction without the CD40-CD40L interaction and Th cell induction without B cells serving as antigen-presenting cells.

Induction of LCMV- or peptide P13-specific Th cells in vivo was comparable in CD40L-, CD40-,- and B cell-deficient mice and in normal C57BL/6 mice as defined by specific proliferation in response to both antigens (Fig. 1). These results demonstrate that LCMV-specific Th cells are induced in vivo independent of a functional CD40-CD40L interaction. Since induction of LCMV-specific Th cells in CD40-deficient as well as in CD40L-deficient mice and B cell-deficient mice was similar, Th cells can apparently be stimulated in vivo without crucial involvement of B cells or of a functional CD40-CD40L interaction after LCMV infection.

In addition, cytokine secretion patterns were analyzed in the supernatants recovered from the proliferation assays performed with LCMV-primed CD4⁺ T cells from CD40-deficient, CD40L-deficient, or control C57BL/6 mice (Fig. 2). IL-2 and IFN-γ were secreted in comparable amounts by CD4⁺ T cells originating from CD40-deficient, CD40L-deficient, or control mice whereas no IL-4 could be detected in the same supernatants (Fig. 2). Thus, the Th1 cytokine secretion pattern which is normally ob-
Figure 2. LCMV-specific cytokine secretion. In vivo LCMV-primed CD40−, CD40L-deficient or control CD4+ T cells were restimulated in vitro with the LCMV-glycoprotein-derived I-Aβ-binding peptide P13 (circles) or without antigen (medium control (squares)). IL-2 content in the supernatants (5,000 EM U correspond to 30 U IL-2/ml) was analyzed 24 h after restimulation (top) whereas IFNγ (OD = 0.5 corresponds to 500 U IFNγ/ml) and IL-4 levels (OD = 0.5 corresponds to 25 U IL-4/ml) were assessed 60 h after restimulation (middle and bottom). Recombinant IL-4 (open circle) served as positive control in the IL-4 ELISA. Each line represents a separate proliferation assay from an individual mouse. One of three equivalent experiments is shown.

Figure 3. Cognate help to CD40-expressing B cells after adoptive transfer of LCMV-primed Th cells. CD40-deficient mice (triangles) and heterozygous littermates (circles) as well as IgM-deficient mice (diamonds) and control mice (circle) were immunized with LCMV. 20 d after infection spleen cells were adoptively transferred into CD40 competent naive recipients and the recipients as well as naive CD40 competent control animals (squares) were challenged with LCMV-DNP. After 9 d, DNP-specific IgG titers were determined by ELISA from 30-fold prediluted sera. Each line represents one individual mouse. One of three similar experiments is shown. Transfer of naive CD4+ cells from CD40−− donors did not result in the generation of significant DNP-specific IgG antibodies (data not shown).

served for LCMV-specific Th cells is not influenced by the absence of functional CD40-CD40L interactions.

In a second experimental approach, induction of LCMV-specific Th cells was assessed in CD40-deficient mice and in heterozygous littermates (both being competent for CD40L on Th cells) by measuring T helper cell function upon transfer of primed Th cells into CD40-competent naive recipients. Thus, CD40L competent cells were primed in a CD40-deficient environment. Adoptive transfer of CD40L-positive, LCMV-primed Th cells into naive recipients with normal CD40+ B cells restores functional T-B cooperation. The conditions for challenging the recipient mice were chosen such that only Th cells already primed in the CD40-deficient donors were able to induce a significant isotype switch in the recipient. To assess the importance of B cells for the induction of Th cells, B cell-deficient mice were included in the experiment. CD40-deficient, B cell-deficient and control mice were infected with LCMV and 18 d after infection spleen cells were transferred into naive recipients. This was followed by a challenge immunization with LCMV-DNP. DNP-specific IgG antibodies were only significantly induced after challenge if LCMV-specific Th cells had been induced in the donor animals before transfer (Fig. 3). Since B cells in the recipients express CD40, equivalent DNP-specific IgG titers in recipients that received primed Th cells from immunized CD40-deficient mice or from heterozygous littermates revealed that induction of LCMV-specific Th cells was not dependent on a functional CD40-CD40L interaction in vivo (Fig. 3, A and B). Similarly, equivalent IgG titers in recipients that received Th cells from LCMV-immunized B cell-deficient mice or B cell-competent C57BL/6 mice indicated that induction of LCMV-specific Th cells was not dependent on the presence of B cells serving as antigen presenting cells (Fig. 3, C and D).

To confirm that the transferred CD4+ T cells were alone responsible for the enhanced DNP-specific IgG titers, purified CD4+ T cells from LCMV-primed CD40-deficient mice or heterozygous littermates were transferred into naive C57BL/6 recipients which were challenged with LCMV-DNP. DNP-specific IgG titers were determined 10 d later (Fig. 4, A and B). In addition, transfer of unseparated spleen cells from LCMV-primed CD40-deficient donors into naive C57BL/6 recipients served as positive control (Fig. 4 C), whereas unmanipulated, unprimed C57BL/6 mice served as negative control. Both CD4+ T cells originating from either LCMV-primed CD40-deficient mice or heterozygous littermates were able to comparably provide help for CD40-competent B cells (Fig. 4, A and B), albeit whole spleen cell transfers resulted in a more pronounced enhancement of DNP-specific IgG titers as compared to purified CD4+ T cells.

Thus, three independent assays showed that the induction of LCMV-specific Th cell responses was not limited by CD40-CD40L interactions and was independent of B cells acting as critical APCs.
Infection of normal mice with LCMV in the hind footpads is critically dependent on functional CD40-CD40L interaction and that a missing ligand in this complex totally abrogates germinal center formation as well as immunoglobulin isotype switch and generation of memory B cells (1-10). To ensure that Ig responses to LCMV as a model viral antigen require CD40-CD40L engagement, we infected CD40-, CD40L-deficient, or C57BL/6 mice with LCMV and then measured antiviral primary antibody responses. VSV was used as a second viral model antigen.

Infection of normal mice with LCMV leads to a pronounced IgG response specific for the nucleoprotein of LCMV (LCMV-NP) (Fig. 5). In contrast, no LCMV-NP-specific IgG titers were obtained using CD40L- or CD40-deficient mice (Fig. 5). Thus, CD40-CD40L interaction is crucial for isotype class switching in response to LCMV infection.

In addition, we analyzed virus neutralizing antibody responses in CD40L-deficient and normal mice after infection with VSV. VSV infection of mice normally induces a type I T-independent neutralizing IgM-response followed by a T-dependent neutralizing IgG response (45-47). As expected control C57BL/6 mice mounted high neutralizing IgM and IgG responses (Fig. 6). In contrast, CD40L-deficient mice mounted a neutralizing T-independent IgM response but no VSV-specific IgG was detected upon VSV infection (Fig. 6). The same results were obtained using CD40-deficient mice (data not shown). These data corroborate previous findings in nonviral systems, demonstrating that cognate T-B cooperation leading to Ig class switching is critically dependent on functional CD40-CD40L interactions.

Th Cell Effector Function: Inflammatory Reaction. Infection of normal mice with LCMV in the hind footpads induces a local inflammatory reaction consisting of two sequential swelling phases. A pronounced swelling reaction mediated by CD8+ T cells is observed 7–10 d after infection; this is followed by a CD4+ T cell-mediated swelling phase declining around day 14–16 after infection (46, 48). The second phase of the swelling reaction exhibits no sharp peak but has the shape of a shoulder. We analyzed whether or not the second swelling phase mediated by LCMV-specific CD4+ T cells was dependent on CD40-CD40L interactions. CD40-deficient mice as well as heterozygous littermates were infected with LCMV in both hind footpads and the subsequent swelling reaction was monitored daily (Fig. 7 A). In fact, there was a tendency noted that CD40-defi-
The swelling reaction was actually CD4+ T cell mediated, CD40L interaction. To confirm that the second phase of induction indicates comparable abilities to mount LCMV-specific infection, we obtained with CD40L-deficient mice (Fig. 7 B). This compatible results upon a functional CD4 molecule. Compatible results the CD4+ T cell-mediated swelling phase was dependent neither the CD8+ T cell-mediated swelling phase nor in dependent peak response and that subsequently the CD4-mice exhibited a slightly increased maximal early CD8-peak response and that subsequently the CD4-dependent shoulder tended to be slightly higher. Thus, neither the CD8+ T cell–mediated swelling phase nor in the CD4+ T cell–mediated swelling phase was dependent upon a functional CD40 molecule. Compatible results were obtained with CD40L-deficient mice (Fig. 7 B). This indicates comparable abilities to mount LCMV-specific inflammatory reactions in the presence or absence of CD40–CD40L interaction. To confirm that the second phase of the swelling reaction was actually CD4+ T cell mediated, C57BL/6 mice were treated with a CD4+ T cell-depleting monoclonal antibody at day 6 and 8 after inoculation with LCMV. Foot pad swelling was less marked and the subsequent decline was much more rapid compared to untreated controls (Fig. 7 B).

**Th Cell Effector Function: Antiviral Protection.** A third Th cell effector function was analyzed in CD40L-deficient and normal mice. VSV primed C57BL/6 mice have been shown to rapidly control replication of a recombinant vaccinia virus expressing the glycoprotein of VSV (VaccGND). This antiviral protective mechanism is virtually exclusively mediated by IFNγ and TNFα which are secreted by VSV glycoprotein–specific CD4+ T cells (37, 49). Neither CD8+ T cells nor VSV-neutralizing antibodies have been shown to be protective in this infection. Because GND is not expressed in the VaccGND envelope, VSV-specific antibodies cannot bind or neutralize VaccGND recombinant virus. CD40L-deficient and normal mice were infected with VSV and 8 d later the VSV primed mice as well as naive control animals were challenged intraperitoneally by infection with VaccGND. Vaccinia titers in the ovaries were determined 5 d after challenge (Fig. 8). As with the foot pad swelling results (Fig. 7 B), we did not observe a reduced CD4+ T cell mediated antiviral effector function in CD40L-deficient as compared to CD40L-competent mice.

**Discussion**

Many reports have focussed on the key importance of the CD40–CD40L interaction for the generation of humoral immune responses (1–6). This was confirmed here for antiviral IgG immune responses. In contrast to most previous reports, this study examined in addition the role of CD40–CD40L interaction on Th cell activation, proliferation and effector functions. Surprisingly, neither Th cell induction nor Th cell effector functions other than cognate help for B cells were compromised by the lack of the CD40- or the CD40L molecules.

CD40 is expressed on different APCs such as dendritic cells and B cells and macrophages (19–23). In addition, it has been shown that CD40–CD40L interaction induces upregulation of MHC class II, B7 and ICAM-1 on dendritic cell lines which potentiate the stimulatory capacity of the APC (50). The CD40–CD40L interaction–dependent upregulation of these and maybe other accessory molecules on the surface of the APC signals then back to the T cell, a process which may be supported by interleukins in addition. Thus, it could be expected that activation and proliferation of specific Th cells would be impaired in the absence of the CD40–CD40L interaction as in fact has been recently reported (51, 52). However, we report here that antigen–specific Th cells are induced normally in vivo in the absence of a functional CD40–CD40L interaction after two different virus infections; hence the formation of this receptor–ligand pair is apparently not critical for the activation of naive virus–specific Th cells. Since B cell activation and proliferation seems to depend critically upon the presence of cognate T-help (5, 7, 53, 54), absence of CD40–CD40L interaction will interfere with proliferation of spe-
specific B cells and therefore reduce class II associated antigen presentation by specific B cells. Because it has been reported that antigen presentation by B cells is important for the normal induction of T-helper cells in several systems (38–44), our results suggest that either B cell proliferation and activation is impaired to a smaller degree than expected in the absence of CD40–CD40L interaction, or, alternatively and more likely, that the presence of specific B cells plays only a minor if any role for the induction of T-helper cells with the infectious virus-derived antigens studied here (55). This latter possibility is supported by the fact, that Th cells primed in the absence of B cells proliferated normally and could mediate isotype switch after adoptive transfer (Fig. 3, C and D). These findings are in contrast to recently presented data (51, 52). Grewal et al. (51) showed a significant impairment of KLH- or HEL-specific T cell priming in mice lacking CD40 ligand. This impairment was evidenced by strongly reduced recall proliferation responses and by a failure of adoptively transferred CD40L-deficient T cells to expand in vivo after antigenic challenge. In contrast to these findings, van Essen et al. observed normal KLH-specific Th cell induction in CD40-deficient mice, but described these KLH-primed T cells as being qualitatively different from T cells primed in a CD40-competent environment; they were apparently not able to provide help to B cells. These differences concerning the importance of a functional CD40-CD40L interaction for the induction and effector functions of T cells between the virus models used in this study and the soluble KLH antigen system used by Grewal et al. (51) and by van Essen et al. (52) probably reflect different critical in vivo mechanisms governing both the induction and effector functions of T cells. There are at least two possible explanations that might account for these differences: (a) The efficient activation of T cells after a viral infection such as with LCMV might over-ride some of the more subtle requirements for responses to soluble protein antigens such as KLH. In addition, the failure of CD40-deficient mice to resolve a Leishmania infection (H. Kikutani, personal communication), despite exhibiting a Leishmania-resistant genetic background, could be due to the lack of CD40 signals to macrophages or dendritic cells which then could lead to a deficit in IL-12 production and therefore to an impaired Th1 development. Additional evidence for a requirement of a functional CD40-CD40L interaction for IL-12 induction in vivo and hence the induction of a Th1 response has recently been presented by Stüber et al. (56). Thus, T helper cells may influence their responses via CD40L indirectly by activating their APCs. In a viral infection the direct secretion of IFN and possibly other interleukins by T cells may render this pathway less critical. (b) Alternatively, B cells may be of key importance as APCs for T cell induction in a soluble antigen system in contrast to virus model infections. There still exists an unresolved controversy on the issue whether B cells play a central role in the initiation of T cell immune responses. Even studies using the same experimental antigen such as KLH as soluble antigen and B cell-deficient mice revealed different results: Epstein et al. (57) reported successful T cell priming in B cell-deficient mice using KLH as antigen whereas Liu et al. (44) failed to obtain T cell priming in B cell-deficient mice using either KLH or OVA as soluble protein antigens. Constant et al. (58) demonstrated that mice lacking B cells were impaired in their priming of T cells to protein but not to peptide antigens. This dominant role of B cells as APCs found in several experimental systems using soluble antigens is possibly abrogated if the CD40 signaling pathway is not functional. We deliberately chose an experimental system where T cell induction is not dependent on B cells functioning as APCs and analyzed the role of CD40-CD40L interaction in T cell priming and T cell effector functions independently of the presence or absence of B cells.

The effector functions of Th cells are differentially influenced by CD40-CD40L interaction. Thymus-dependent Ig-isotype switched humoral immune responses are completely abrogated in CD40- or CD40L-deficient mice whereas thymus-independent IgM-responses to VSV are comparable to normal mice; the latter apparently do not require a functional interaction between CD40 and its ligand. Although T-helper cells do not induce antibody isotype switching in B cells in the absence of CD40-CD40L interaction, CD4+ T cells could be functionally primed in CD40-deficient mice since upon transfer they were able to provide help for CD40-competent B cells to undergo isotype switch. These findings are in contrast to the recent data of van Essen et al. (52) showing that KLH-specific T cells primed in a CD40-deficient environment are not able to help CD40-competent B cells. Although the experimental setups are not identical, it can be concluded that Th cell priming by virus infection seems to be considerably more efficient in a CD40-deficient environment than is possible for soluble protein antigens. Not only were induction, proliferation and cytokine production of specific T-helper cells normal in the absence of CD40-CD40L interaction but also effector functions of T-helper cells other than mediating Ig isotype switching were largely normal in the absence of CD40 or CD40L. CD4+ T cell mediated inflammatory reaction upon LCMV infection was not impaired in CD40- or CD40L-deficient mice. In addition, Th cell-dependent antiviral protection was not impaired by the lack of CD40-CD40L interaction: activated VSV-specific Th cells in CD40L-deficient mice were able to inhibit the replication of VSV-G recombinant vaccinia virus by a cytokine mediated effector function; this protective Th cell function has been shown to be mediated by release of IFNγ and TNFα by activated CD4+ Th cells (37). It has recently been suggested, that CD40L may exert a direct protective effect against vaccinia virus (59). Our data show that Th cells can efficiently protect against vaccinia virus replication also in the absence of CD40L, suggesting that this parameter is not limiting under the conditions tested in vivo.

In conclusion, these results reveal a dichotomy in the role of the CD40-CD40L interaction in Th cell effector functions: the functional interaction is of critical importance in T-B cell cooperation for the induction of thymus-dependent humoral immune responses but the same inter-
action is not limiting for Th cell mediated effector functions such as virus-induced inflammatory reactions or antiviral protection, which probably depend on interactions between Th cells with macrophages and/or dendritic cells. Our data strongly suggest that CD40-CD40L interaction divides antiviral Th cell effector functions in two categories: one category consisting of cognate T help mediating B cell activation followed by Ig class switching which is strictly dependent on a functional CD40-CD40L interaction; and a second category, represented in this report by virus-induced, CD4\(^+\) T cell-mediated inflammatory reaction as well as antiviral protection is largely independent of a functional CD40-CD40L interaction. Similarly, activation and proliferation of Th cells, albeit not a Th cell effector function, may be placed in this second category. Thus, CD40-CD40L interaction is critically and probably unidirectionally-needed for B cell activation followed by Ig class switch, but in addition is possibly of importance for macrophage/dendritic cell activation especially in the case of nonviral antigens.

We thank Werner Müller and Klaus Rajewsky for generously providing us with the IgM-deficient mice. We thank Awen Gallimore for helpful discussions, Alana Althage for excellent technical help, and Yvonne Deforlin for secretarial assistance.

This work was supported by grants from the Swiss National Science Foundation (21–32179.91) and the Kanton of Zürich, Switzerland and the Human Science Frontier Program.

Address correspondence to Annette Oxenius, Institute of Experimental Immunology, Schmelzbergstr. 12, CH-8091 Zürich, Switzerland. F.M. Bachmann’s present address is Ontario Cancer Institute/Princess Margaret Hospital, Toronto M5G2C1, Ontario, Canada.

Received for publication 9 November 1995 and in revised form 26 February 1996.

References

1. Noelle, R.J., M. Roy, D.M. Shepherd, I. Stamenkovic, J.A. Ledbetter, and A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA. 89: 6550–6554.

2. Lederman, S., M.J. Yellin, A. Krichevsky, J. Belko, J.J. Lee, and L. Chess. 1992. Identification of a novel surface protein on activated CD4\(^+\) T cells that induces contact-dependent B cell differentiation. J. Exp. Med. 175:1091–1101.

3. Lederman, S., M.J. Yellin, G. Inghirami, J.J. Lee, D.M. Knowles, and L. Chess. 1992. Molecular interaction mediating T-B lymphocyte collaboration in human lymphoid follicles. J. Immunol. 149:3817–3826.

4. Parker, D.C. 1993. T cell-dependent B cell activation. Annu. Rev. Immunol. 11:331–360.

5. Foy, T.M., J.D. Laman, J.A. Ledbetter, A. Aruffo, E. Claassen, and R.J. Noelle. 1994. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 180:157–163.

6. Banchereau, J., F. Bazan, D. Blanchard, F. Brière, J.P. Galizzi, C. van Kooten, Y.J. Liu, F. Roussel, and S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881–922.

7. Foy, T.M., D.M. Shepherd, F.H. Durie, A. Aruffo, J.A. Ledbetter, and R.J. Noelle. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. 178:1567–1575.

8. Van den Eertwegh, A.J.M., R.J. Noelle, M. Roy, D.M. Shepherd, A. Aruffo, J.A. Ledbetter, W. Boersma, and E. Claassen. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178:1555–1565.

9. Gray, D., P. Dullforce, and S. Jainandunings. 1994. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J. Exp. Med. 180:141–155.

10. Lane, P., T. Brocker, S. Hubele, E. Padovan, A. Lanzavecchia, and F. McConnell. 1993. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J. Exp. Med. 177:1209–1213.

11. Renshaw, B.R., W.C. Fanslow, R.J. Armitage, K.A. Campbell, D. Liggitt, B. Wright, B.L. Davison, and C.R. Maliszewski. 1994. Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. 180:1889–1900.

12. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40 ligand-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity. 1:167–178.

13. Xu, J., T.M. Foy, J.D. Laman, E.A. Elliott, J.J. Dunn, T.J. Waldschmidt, J. Ekemore, R.J. Noelle, and R.A. Flavell. 1994. Mice deficient for the CD40 Ligand. Immunity. 1:423–431.

14. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L.S. Grosmaire, R. Stenberg, M. Neubauer et al. 1993. The CD40 ligand, gp 39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 72:291–300.

15. Allen, R.C., R.J. Armitage, M.E. Conley, H. Rosenblatt, N.A. Jenkins, N.G. Copeland, M.A. Bedell, S. Edelhoff, C.M.
Disteche, and D.K. Simoneaux. 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome (see comments). Science (Wash. DC). 259:990–993.

16. Korthauer, U., D. Graf, H.W. Mages, F. Brière, P. Munroedevi, S. Malcolm, A.G. Ugazio, L.D. Notarangelo, R.J. Levinsky, and R.A. Kroczek. 1993. Defective expression of T cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (Lond.). 361:539–541.

17. Disanto, J.P., J.Y. Bonnefoy, J.F. Gauchat, and A. Fischer. 1993. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature (Lond.). 361:541–543.

18. Farrington, M., L.S. Grosmaire, S. Nonoyama, S.H. Fischer, D. Hollenbaugh, J.A. Ledbetter, J.L. Noelle, A. Aruffo, and H.D. Ochs. 1994. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc. Natl. Acad. Sci. USA. 91:1099–1103.

19. Ling, N.R., I.C.M. MacLennan, and D. Mason. 1987. In Leucocyte Typing III: B-Cell and Plasma Cell Antigens: New and Previously Defined Clusters. A.J. McMichael, editor. Oxford University Press, Oxford. 302–335.

20. Freudenthal, P.S., and R.M. Steinnmann. 1990. The distinct surface of human blood dendritic cells, as observed after an impoved isolation method. Proc. Natl. Acad. Sci. USA. 87: 7698–7702.

21. Schrieber, F., A.S. Freedman, G. Freeman, E. Messner, G. Lee, J. Daley, and L.M. Nadler. 1989. Isolated follicular dendritic cell display a unique antigenic phenotype. J. Exp. Med. 169:2043–2048.

22. Clark, E.A., K.H. Grabstein, and G.L. Shu. 1992. Cultures human follicular dendritic cells. Growth characteristics and interaction with B lymphocytes. J. Immunol. 148:3327–3335.

23. Galy, A.H.M., and H. Spits. 1992. CD40 is functionally expressed on human thymic epithelial cells. J. Immunol. 149: 775–782.

24. Kitamura, D., J. Roes, R. Kühn, and K. Rajewski. 1992. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin m chain gene. Nature (Lond.). 350:423–426.

25. Mackett, M., T. Yilma, J.K. Rose, and B. Moss. 1985. Vaccinia virus recombinants: expression of VSV genes and capture activity of mice and cattle. Science (Wash. DC). 227;433–435.

26. Battegay, M., D. Moskophidis, H. Waldner, M.A. Bründler, Fung, W.P. Leung, T.W. Mak, H. Hengartner, and R.M. Zinkernagel. 1993. Impairment and delay of neutralizing antiviral antibody responses by virus specific cytotoxic T cells. J. Immunol. 151:5408–5415.

27. Matsuda, Y., R.D. Possee, H.A. Overton, and D. Bishop. 1987. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol. 68:1233–1250.

28. Oxenius, A., M.F. Bachmann, P.G. Ashton-Rickardt, S. Tonegawa, R.M. Zinkernagel, and H. Hengartner. 1995. Presentation of endogenous viral proteins in association with major histocompatibility complex II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur. J. Immunol. 25:3402–3411.

29. Pruslin, F.H. 1991. Caveats and suggestions for the ELISA. J. Immunol. Methods. 137:27–35.

30. Chirmule, N. 1991. Misinterpretation of results of cytokine bioassays. J. Immunol. Methods. 137:141–144.

31. Mishell, B.B., and S.M. Shiigi. 1980. Selected Methods in Cellular Immunology. Freeman and Company, San Francisco. 347–350.

32. Charan, S., H. Hengartner, and R.M. Zinkernagel. 1986. Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: analysis in a viral model. Proc. Natl. Acad. Sci. USA. 83:2604–2608.

33. Roost, H.P., S. Charan, and R.M. Zinkernagel. 1990. Analysis of the kinetics of antiviral memory T help in vivo: characterization of short lived cross-reactive T help. Eur. J. Immunol. 20:2547–2554.

34. Scott, D.W., and R.K. Gershon. 1970. Determination of total and mercaptoethanol-resistant antibody in the serum sample. Clin. Exp. Immunol. 6:13–18.

35. Castelmur, I., C. DiPaolo, M.F. Bachmann, H. Hengartner, R.M. Zinkernagel, and T.M. Kündig. 1993. Comparison of the sensitivity of in vivo and in vitro assays for detection of antiviral cytotoxic T cell activity. Cell. Immunol. 151:460–466.

36. Cobbold, S.P., A. Jayasuriya, A. Nash, T.D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.). 312:548–551.

37. Binder, D., and T.M. Kündig. 1991. Antiviral protection by CD8+ versus CD4+ T cells: CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent interleukins. J. Immunol. 146:4301–4307.

38. Lawton, A.R., R. Asfawsky, and M.B. Hylton. 1972. Suppression of immunological synthesis in mice. I. Effect of treatment with antibodies to u-chain. J. Exp. Med. 135:277–286.

39. Ron, Y., J. DeBaetscher, J. Gordon, J. Feldmann, and S. Segal. 1981. Defective induction of antigen-reactive proliferating T cells in B-cell deprived mice. J. Immunol. 11:964–968.

40. Janeway, C.A., Y. Ron, and K.E. Katz. 1987. The B cell is the initiating antigen-presenting cells in the peripheral lymph nodes. J. Immunol. 138:1051–1055.

41. Ron, Y., and J. Sprent. 1987. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J. Immunol. 138:2848–2856.

42. Kurt-Jones, E.A., E.D. Liano, K.A. Hayglass, B. Benacerraf, M.S. Sym, and A.K. Abbas. 1988. The role of antigen-presenting B cells in vivo: studies of B deficient mice. J. Immunol. 140:3773–3778.

43. van Ewijk, W., Y. Ron, J. Monaco, J. Kappler, P. Marrack, C. Meur, P. Gerlinger, B. Durand, C. Benoist, and D. Mathis. 1988. Compartmentalization of MHC class II gene expression in transgenic mice. Cell. 53:357–370.

44. Liu, Y., L. Rammathanin, Y. Guo, D. Huszar, M. Trounstone, and M. Zhao. 1995. Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int. Immunol. 7:1353–1362.

45. Bachmann, M.F., R.U. Hoffmann, T.M. Kündig, K. Bürki, H. Hengartner, and R.M. Zinkernagel. 1993. The influence of antigen organisation on B cell responsiveness. Science (Wash. DC). 262:1448–1451.

46. Leist, T.P., S.P. Cobbold, H. Waldmann, M. Aguet, and R.M. Zinkernagel. 1987. Functional analysis of T lymphocyte subsets in antiviral host defense. J. Immunol. 138:2278–2281.

47. Bachmann, M.F., H. Hengartner, and R.M. Zinkernagel. 1995. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B.
cell induction? *Eur. J. Immunol.* 25:3445–3451.

48. Moskophidis, D., and G.F. Lehmann. 1989. Virus-induced delayed-type hypersensitivity reaction is sequentially mediated by CD8+ and CD4+ T lymphocytes. *Proc. Natl. Acad. Sci. USA.* 86:3291–3295.

49. Kündig, T., I. Castelmur, M.F. Bachmann, D. Abraham, D. Binder, H. Hengartner, and R.M. Zinkernagel. 1993. Fewer protective cytotoxic T cell epitopes than T helper cell epitopes on vesicular stomatitis virus. *J. Virol.* 67:3680–3683.

50. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J. Exp. Med.* 179:1109–1118.

51. Grewal, I.S., J. Xu, and R.A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. *Nature (Lond.)* 378:617–620.

52. van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. *Nature (Lond.)* 378:620–623.

53. Han, S., K. Hathcock, B. Zheng, T.B. Kepler, R. Hodes, and G. Kelsoe. 1995. Cellular interaction in germinal centers. *J. Immunol.* 155:556–567.

54. Nishioka, Y., and P.E. Lipsky. 1994. The role of CD40-CD40 ligand interaction in human T cell-B collaboration. *J. Immunol.* 153:1027–1036.

55. Cerny, A., A.W. Hügin, S. Sutter, H. Bazin, H. Hengartner, and R.M. Zinkernagel. 1986. Immunity to lymphocytic choriomeningitis virus in B cell-depleted mice: evidence for B cell and antibody independent protection by memory T cells. *Eur. J. Immunol.* 16:913–917.

56. Süster, E., W. Strober, and M. Neurath. 1996. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. *J. Exp. Med.* 183:693–698.

57. Epstein, M.M., F. Di Rosa, D. Jankovic, A. Sher, and P. Matzinger. 1995. Successful T cell priming in B cell-deficient mice. *J. Exp. Med.* 182:915–922.

58. Constant, S., N. Schweitzer, J. West, P. Ranney, and K. Bottomly. 1995. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. *J. Immunol.* 155:3734–3741.

59. Ruby, J., H. Bluethmann, M. Aguet, and I.A. Ramshaw. 1995. CD40 ligand has potent antiviral activity. *Nat. Med.* 1:437–441.